sac-TMT plus EGFR-TKI
Phase 2Small molecule
sac-TMT plus EGFR-TKI is one of 4 small molecule programs targeting Sacituzumab Tirumotecan. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Sacituzumab Tirumotecan
#DrugCompanyPhaseTrials
1Trodelvy
GileadPhase 2
Sacituzumab Tirumotecan
Merck & Co.Phase 2
Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 2
sac-TMT plus EGFR-TKI
ZZhejiang Cancer Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sac-TMT plus EGFR-TKI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZhejiang Cancer Hospital